Honeywell beats Q3 estimates, reiterates spinoff plans, and reports record backlog amid strong organic growth and improved free cash flow margin.
Moderna halts development of its experimental CMV vaccine after Phase III trial fails to meet primary endpoint, leaving the field without an approved congenital CMV vaccine.
Honeywell beats Q3 estimates, reiterates spinoff plans, and reports record backlog amid strong organic growth and improved free cash flow margin.
Moderna halts development of its experimental CMV vaccine after Phase III trial fails to meet primary endpoint, leaving the field without an approved congenital CMV vaccine.